<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335087">
  <stage>Registered</stage>
  <submitdate>26/01/2010</submitdate>
  <approvaldate>26/02/2010</approvaldate>
  <actrnumber>ACTRN12610000177055</actrnumber>
  <trial_identification>
    <studytitle>Comparison of efficacy and cognitive side effects of bifrontal and bitemporal electroconvulsive therapy (ECT) for major depression</studytitle>
    <scientifictitle>Comparison of efficacy and cognitive side effects of bifrontal and bitemporal electroconvulsive therapy (ECT) for major depression</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Electrode placement in electroconvulsive therapy</healthcondition>
    <healthcondition>Major depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bifrontal electrode placement, with each electrode placed 5 cm above the outer angle of the orbit on a line parallel to the sagittal plane. Treatment was given with a square-wave, brief-pulse, constant-current device for stimulating a seizure lasting a minimum of 20 seconds going up to a maximum of 60 seconds. It was administred three times a week, until remission or completing twelve treatments.</interventions>
    <comparator>Bitemporal electrode placement, with each electrode placed on the perpendicular line 3 cm above the midpoint of the line joining the external auditory meatus and the outer canthus of the eye. Treatment was given with a square-wave, brief-pulse, constant-current device for stimulating a seizure lasting a minimum of 20 seconds  going up to a maximum of 60 seconds. It was administred three times a week, until remission or completing twelve treatments.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Severity of depression, as measured by the Montgomery and Asberg Depression Rating Scale (MADRS)</outcome>
      <timepoint>At baseline and at 9,18 and 27 days after intervention commenced</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cognitive deficits, as measure by the Rey Auditory Verbal Learning Test (RAVLT)</outcome>
      <timepoint>At baseline and at 9,18 and 27 days after intervention commenced</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of depression, as measured by the Clinical Global Impression(CGI) score</outcome>
      <timepoint>At baseline and at 9,18 and 27 days after intervention commenced</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive deficits, as measured by the Mini-Mental State Examination (MMSE)</outcome>
      <timepoint>At baseline and at 9,18 and 27 days after intervention commenced</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Major depressive episode in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, with scores &gt; or = 21 in MADRS and &gt; or = 4 in CGI</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior diagnosis of schizophrenia, schizoaffective disorder, rapid-cycling bipolar disorder, substance dependence, dementia, neuropsychiatric disorders or severe non-psychiatric diseases; ECT treatment in the previous six months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/05/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>31</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>IPSEMG/ Hospital Governador Israel Pinheiro</primarysponsorname>
    <primarysponsoraddress>Alameda Ezequiel Dias, 225, 11o. andar,
Santa Efigenia.
Belo Horizonte - MG
ZIP code 30130-110</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Paulo Jose Ribeiro Teixeira</sponsorname>
      <sponsoraddress>Rua Fernandes Tourinho, 470, sl. 903.
Belo Horizonte- MG
ZIP code 30112-000</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Comparison of efficacy and cognitive side effects of bifrontal and bitemporal ECT for major depression</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisa- CEP/HGIP</ethicname>
      <ethicaddress>Alameda Ezequiel Dias, 225, 11o. andar,
Santa Efigenia.
Belo Horizonte - MG
ZIP code 30130-110</ethicaddress>
      <ethicapprovaldate>15/05/2000</ethicapprovaldate>
      <hrec>026/00</hrec>
      <ethicsubmitdate>25/04/2000</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paulo Jose Ribeiro Teixeira</name>
      <address>Rua Fernandes Tourinho, 470, sl. 903.
Belo Horizonte - MG
ZIP Code 30112-000</address>
      <phone>+55 31 3227-0030</phone>
      <fax />
      <email>teixeirapaulo@uol.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paulo Jose Ribeiro Teixeira</name>
      <address>Rua Fernandes Tourinho, 470, sl. 903.
Belo Horizonte - MG
ZIP Code 30112-000</address>
      <phone>+55 31 3227-0030</phone>
      <fax />
      <email>teixeirapaulo@uol.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>